Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Medical Specialties
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| TMO | Thermo Fisher Scientific, Inc. | 0.98% | 628.33 | 1.0% | $845.71m | |
| DHR | Danaher Corp. | 2.13% | 313.45 | 0.7% | $787.97m | |
| MDT | Medtronic Plc | 1.82% | 112.25 | 0.6% | $721.69m | |
| ABT | Abbott Laboratories | -0.03% | 132.43 | 0.8% | $684.68m | |
| ISRG | Intuitive Surgical, Inc. | 5.16% | 340.49 | 0.8% | $527.81m | |
| DXCM | DexCom, Inc. | 6.48% | 558.40 | 7.8% | $419.12m | |
| BDX | Becton, Dickinson & Co. | 1.73% | 250.39 | 1.0% | $383.76m | |
| SYK | Stryker Corp. | 2.41% | 260.54 | 1.3% | $373.40m | |
| BSX | Boston Scientific Corp. | 1.72% | 41.40 | 1.0% | $362.00m | |
| ALGN | Align Technology, Inc. | 4.35% | 666.72 | 6.4% | $339.55m | |
| EW | Edwards Lifesciences Corp. | 3.22% | 115.56 | 0.4% | $288.80m | |
| A | Agilent Technologies, Inc. | 1.63% | 153.94 | 1.6% | $259.09m | |
| ZBH | Zimmer Biomet Holdings, Inc. | 2.33% | 128.41 | 1.7% | $232.19m | |
| IDXX | IDEXX Laboratories, Inc. | 3.25% | 611.43 | 3.8% | $226.28m | |
| PKI | PerkinElmer, Inc. (United States) | 2.16% | 185.40 | 2.4% | $173.66m |
Company Profile
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.